Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Rhenman & Partners Asset Management AB

Rhenman & Partners Asset Management AB increased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 11.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 43,457 shares of the biopharmaceutical company’s stock after buying an additional 4,457 shares during the quarter. Regeneron Pharmaceuticals comprises approximately 3.2% of Rhenman & Partners Asset Management AB’s investment portfolio, making the stock its 5th largest holding. Rhenman & Partners Asset Management AB’s holdings in Regeneron Pharmaceuticals were worth $30,956,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the business. Resona Asset Management Co. Ltd. acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter worth $26,507,000. Pamalican Asset Management Ltd purchased a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at $4,915,000. Orion Investment Co grew its position in Regeneron Pharmaceuticals by 1.7% during the 4th quarter. Orion Investment Co now owns 29,886 shares of the biopharmaceutical company’s stock worth $21,289,000 after purchasing an additional 500 shares during the period. Thoroughbred Financial Services LLC raised its stake in shares of Regeneron Pharmaceuticals by 20.8% during the 4th quarter. Thoroughbred Financial Services LLC now owns 592 shares of the biopharmaceutical company’s stock valued at $421,000 after buying an additional 102 shares during the last quarter. Finally, Atlas Capital Advisors Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 5,620.3% in the 4th quarter. Atlas Capital Advisors Inc. now owns 8,466 shares of the biopharmaceutical company’s stock valued at $6,031,000 after buying an additional 8,318 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $573.45 on Friday. Regeneron Pharmaceuticals, Inc. has a one year low of $572.00 and a one year high of $1,211.20. The stock has a market cap of $62.69 billion, a PE ratio of 14.98, a P/E/G ratio of 2.34 and a beta of 0.27. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The stock has a 50 day moving average price of $676.70 and a 200 day moving average price of $781.68.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The business had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period last year, the company earned $11.86 EPS. Equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.61%. The ex-dividend date of this dividend was Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 2.30%.

Analyst Ratings Changes

Several analysts recently commented on REGN shares. Leerink Partners raised Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and raised their target price for the stock from $762.00 to $834.00 in a report on Wednesday, February 5th. JPMorgan Chase & Co. dropped their price objective on shares of Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an “overweight” rating on the stock in a research note on Monday, March 31st. Robert W. Baird decreased their target price on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating for the company in a research note on Wednesday, February 5th. Truist Financial dropped their price target on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a research report on Wednesday, January 8th. Finally, Sanford C. Bernstein cut their price objective on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a report on Tuesday, January 7th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $966.88.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.